China Life Science Sector Overview 2022: Wading into Deep Waters: Survive and Thrive

The Chinese government has been deepening its reform over the past year in order to foster evolving regulatory framework. Deeper reforms coupled with a chilled market means life science companies should prioritize their assets and re-position their business strategies in order to survive and grow stronger.

15 minute readJanuary 30, 2023 at 09:36 AM

Susan Mok

China Life Science Sector Overview 2022: Wading into Deep Waters: Survive and Thrive

Summary

Innovation-driven regulatory environment and economic downturn in the past year have urged life science companies to be more resilient and flexible to current regulatory and market changes.

The Chinese government has cultivated an innovation-driven regulatory environment and provide unprecedented market incentives for orphan drugs and pediatric drugs.

A Subscription is Required to Access this Content

Subscribe to China Law & Practice today for:

✓ A database of 3000+ essential documents, including key PRC laws translated into English
✓ Newsletters with business-critical and sector-specific updates
✓ Premium mobile access with timely analysis on China's fast-changing market

Already a Subscriber? Log In. Sign In Now

Questions? Contact us at [email protected] | 1-855-808-4530 (Americas) | 44(0) 800 098 386009 (UK & Europe)